Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?
Exploration of Medicine · 19.11.2026 · 7
DOI: 10.37349/emed.2026.1001440 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Medicine, online erschienen am 19.11.2026. Verfasst von Amedeo Lonardo und 1 weiteren Autor:innen. Die Arbeit nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recent changes in steatotic liver disease (SLD) nomenclature, together with a broader view of adiposity and metabolic health, require renewed appraisal of SLD in lean individuals. This review evaluates the clinical relevance of lean nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD), and metabolic dysfunction-associated SLD (MASLD) by integrating meta-analytic evidence, emerging MAFLD data, and original MASLD studies. Across definitions, while obesity is a risk factor for SLD development and progression, leanness does not confer protection. Lean NAFLD accounts for a substantial share of the global disease burden and is associated with steatohepatitis, advanced fibrosis, cirrhosis, incident diabetes, liver-related and all-cause mortality, and selected extrahepatic outcomes, despite a generally more favorable cardiometabolic profile than obesity-associated disease. Lean MAFLD is less prevalent but clinically important, with evidence of excess liver-related mortality. Early MASLD studies similarly show that body mass index (BMI) can underestimate hepatic, cardiovascular, and survival risk. Genetic, epigenetic, demographic and ethnic factors further shape disease susceptibility and progression. Overall, the evidence supports moving from weight-based classification to risk-based assessment incorporating fibrosis stage, metabolic dysfunction, visceral adiposity, sarcopenia, age, sex, ethnicity and genetic risk. Thus, ‘lean’ should not be regarded as a low-risk state, but as a phenotype in which conventional obesity metrics may obscure clinically meaningful disease. Future studies should harmonize definitions, clarify causal pathways, refine phenotyping beyond BMI, and ensure adequate representation of lean individuals in therapeutic, prognostic, and surveillance studies of all SLD variants.
Zitieren
APA
Lonardo, A., & Weiskirchen, R. (2026). Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?. Exploration of Medicine, 7. https://doi.org/10.37349/emed.2026.1001440
Vancouver
Lonardo A, Weiskirchen R. Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?. Exploration of Medicine. 2026;7. doi:10.37349/emed.2026.1001440
BibTeX
@article{Lonardo2026,
author = {Lonardo, Amedeo and Weiskirchen, Ralf},
title = {Is the “Lean NAFLD/MAFLD/MASLD” nosography construct still clinically useful and scientifically warranted?},
journal = {Exploration of Medicine},
year = {2026},
volume = {7},
doi = {10.37349/emed.2026.1001440}
}
EUVIMED